STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
An FDA advisory panel has recommended updating this fall's Covid vaccines to target the fast-growing XFG variant, while Pfizer has entered a $10.5 billion deal with China's Innovent Biologics to develop early-stage cancer treatments. Additionally, the WHO has identified three drugs to be fast-tracked for clinical testing in response to the current Ebola outbreak.
Pfizer's substantial $10.5 billion collaboration with China's Innovent Biologics to develop 12 early-stage cancer medicines highlights the strategic importance of China's biotech pipeline. For professionals tracking investment opportunities, this could signal a lucrative area for growth and partnership, particularly in antibody-drug conjugates and multi-specific antibodies, given the region's rising deal value to $137.7 billion last year.